Company news
Outlook Therapeutics, Inc. (NASDAQ:OTLK) news
Every Outlook Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
August 27, 2026
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
August 12, 2026
Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
August 12, 2026
Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD
July 24, 2026
Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA as a Treatment for Wet AMD
June 17, 2026
Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a...
June 16, 2026
Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
June 1, 2026
Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
May 28, 2026
Sapu Nano Unveils Progress in Deciparticle™ Nanomedicine Platform and AI-Driven Oncology Development at BIO 2026
May 28, 2026
Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
May 26, 2026
Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
May 15, 2026
Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
April 23, 2026
Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
April 22, 2026
Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
April 21, 2026
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA
April 7, 2026
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
March 25, 2026
Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering
March 24, 2026
Outlook Therapeutics Announces Proposed Public Offering
March 23, 2026
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note
March 16, 2026
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)
March 5, 2026
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevac...
February 19, 2026
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
February 17, 2026
Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter
February 11, 2026
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development
January 6, 2026
Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for ...
December 31, 2025
Outlook Therapeutics Announces New Employment Inducement Grants
December 26, 2025
Outlook Therapeutics Reports Financial Results for Fiscal Year 2025
December 19, 2025
Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
November 24, 2025
Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
November 13, 2025
Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010
November 3, 2025
Outlook Therapeutics Provides Update on Type A Meeting with FDA
September 29, 2025
Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)
September 3, 2025
Outlook Therapeutics Requests Type A Meeting with FDA
September 2, 2025
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update
August 14, 2025
Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
July 24, 2025
Outlook Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
July 22, 2025
Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer
July 1, 2025
Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event
June 18, 2025
Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
June 10, 2025
Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD
June 2, 2025
Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering
May 23, 2025
Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants
May 22, 2025
Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update
May 15, 2025
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
April 8, 2025
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administ...
February 28, 2025
Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
February 19, 2025
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update
February 14, 2025
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment
February 4, 2025
Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors
January 31, 2025
Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the T...
January 23, 2025